Anti-CD20 antibody rituximab is now essential for the treatment of CD20-positive B-cell lymphomas. Decreased expression of CD20 is one of the major mechanisms underlying both innate and acquired resistance to rituximab. In this study, we show that histone deacetylase (HDAC) inhibitors augment the cytotoxic activity of rituximab by enhancing the surface expression of CD20 antigen on lymphoma cells. HDAC inhibitors, valproic acid (VPA) and romidepsin, increased CD20 expression at protein and mRNA levels in B-cell lymphoma cell lines with relatively low CD20 expression levels. The VPA-mediated increase in CD20 expression occurred at 1 mM, which is clinically achievable and safe, but insufficient for inducing cell death. Chromatin immunoprecipitation assays revealed that HDAC inhibitors transactivated the CD20 gene through promoter hyperacetylation and Sp1 recruitment. HDAC inhibitors potentiated the activity of rituximab in complementdependent cytotoxic assays. In mouse lymphoma models, HDAC inhibitors enhanced CD20 expression along with histone hyperacetylation in transplanted cells, and acted synergistically with rituximab to retard their growth. The combination with HDAC inhibitors may serve as an effective strategy to overcome rituximab resistance in B-cell lymphomas.
Introduction
Rituximab is a chimeric monoclonal antibody that binds to the pan-B-cell marker CD20, which is expressed in B90% of B-cell lymphomas. 1 On engagement with CD20, rituximab kills target cells through complement-dependent cytotoxicity and antibodydependent cellular cytotoxicity, as well as direct activation of the cell death program. 2 Since being approved for clinical use in 1997, rituximab has given great benefits to patients with B-cell lymphomas, and has changed the paradigm of the treatment of indolent lymphomas. 3, 4 Recently, rituximab resistance has emerged as an important clinical issue. 5 Although several mechanisms are proposed, loss of CD20 expression is undoubtedly one of the most straightforward and frequent causes of both innate and acquired resistance to rituximab in B-cell malignancies. It has been shown that the low response rate to rituximab is attributable to dim CD20 expression in chronic lymphocytic leukemia or small lymphocytic lymphoma 6 and Burkitt lymphoma. 7 In a cohort of diffuse large B-cell lymphoma, patients with low CD20 expression have a poor prognosis. 8 Furthermore, several cases of CD20-negative relapse were identified after treatment with rituximab-based regimens in diffuse large B-cell lymphoma. 9, 10 Recently, Hiraga et al. 11 reported that relapse or disease progression was observed in B30% of patients with B-cell lymphomas treated with rituximab-containing chemotherapies, and CD20 expression was lost in 5 of 19 relapsed patients who underwent repeated biopsy. It is of note that DNAdemethylating agents restored CD20 expression in lymphoma cells isolated from these patients, suggesting that epigenetic mechanisms underlie the downregulation of CD20 after rituximab treatment.
Epigenetics has a pivotal role in many pathological processes of cancer. 12 Accumulating evidence indicates that histone deacetylases (HDACs) are at the center of cancer epigenetics. 13 HDACs are a family of enzymes that catalyze the removal of acetyl groups from core histones, which results in chromatin compaction and transcriptional repression. 14 In leukemic cells, chromosomal translocation-generated fusion proteins, such as PML/RARa and AML-1/ETO, form a complex with HDACs, and aberrantly suppress the expression of genes required for cell differentiation and growth control, leading to the transformation of hematopoietic stem/progenitor cells. 13 In addition, HDAC overexpression is observed in various cancers, such as colon cancer, 15 malignant melanoma 16 and acute leukemia, 17 in association with histone hypoacetylation, which causes transcriptional repression of genes related to cell-cycle control, cell differentiation and apoptosis. Recent literature suggests that HDACs are also implicated in the drug resistance of B-cell malignancies such as multiple myeloma. 18, 19 Given the causative role of HDACs in cancer, small molecular inhibitors of HDACs are expected to constitute a novel class of anticancer drugs. HDAC inhibitors are able to restore the expression of genes that are aberrantly repressed in tumor cells, leading to cell-cycle arrest, differentiation and apoptosis. 20 In addition, it has been reported that HDAC inhibitors epigenetically modify the expression of cell surface molecules, such as tumor antigens (gp100 21 and NKG2D ligands 22 ), death receptors (tumor necrosis factor receptor type I 23 and DR5
24
) and immunoregulatory molecules (CD86 25 and MHC II DRA 26 ), in various tumors and immune effector cells. This property may broaden the application of HDAC inhibitors to the area of chemosensitization and cancer immunotherapy. In this study, we investigated whether HDAC inhibitors could enhance the expression of surface CD20 antigen on B-cell lymphoma cells to enforce the cytotoxic activity of rituximab.
Materials and methods

Cells and cell culture
We used five Burkitt lymphoma-derived cell lines (Daudi, BJA-B, Namalwa, Raji and Ramos), two diffuse large B-cell lymphoma cell lines (TK and B104) and a mantle lymphoma cell line (HBL-2) in this study. These cell lines were purchased from the Health Science Research Resources Bank (Osaka, Japan), except for HBL-2, 27 which was provided by Dr Masafumi Abe (Department of Pathology, Fukushima Medical University, Fukushima, Japan).
Drugs
HDAC inhibitors, valproic acid (VPA) and romidepsin (formerly known as FK228 or depsipeptide), were provided by Kyowa Hakko Kirin Co (Tokyo, Japan) and Gloucester Pharmaceuticals (Cambridge, MA, USA), respectively. We purchased rituximab from Zenyaku Kogyo Co (Tokyo, Japan).
Complement-dependent cytotoxicity assays
We carried out complement-dependent cytotoxicity assays as described by Stein et al. 28 with minor modifications. Cells were plated at 62 500 cells per well in black 96-well plates and incubated for 24 h with serially diluted rituximab in the presence of human complement (Quidel, SanDiego, CA, USA) at the final dilution of 1:4. Viable cell numbers were quantitatively measured with modified (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium) (MTT) assays using Cell Counting Kit-8 (Dojindo Molecular Technologies, Rockville, MD, USA).
Flow cytometry
We detected the surface expressions of CD20, CD10, CD21, CD43 and CD44 using specific antibodies against each molecule (eBioscience, San Diego, CA, USA) along with the corresponding isotype-matched controls using a FACSaria flow cytometer (Becton Dickinson, Bedford, MA, USA), as previously described. 29 We also used a phycoerythrin-conjugated annexin-V antibody (BD Biosciences, San Jose, CA, USA) for quantitative assessment of apoptosis.
Immunoblotting
Immunoblotting was carried out according to the standard method using anti-human CD20 monoclonal (clone 2H7; eBioscience) and anti-GAPDH polyclonal (Santa Cruz Biotechnology, Santa Cruz, CA, USA) antibodies.
Real-time quantitative reverse transcription PCR
Total cellular RNA was reverse-transcribed into cDNA using SuperScript reverse transcriptase and oligo(dT) primers (Invitrogen, Carlsbad, CA, USA), and subjected to real-time quantitative reverse transcription PCR using Power SYBR Green PCR Master Mix (Applied Biosystems, Warrington, UK) and the following primers: CD20 sense, 5 0 -ATGAAAGGCCCTATTGCTATG-3 0 ; CD20 antisense, 5 0 -GCTGGTTCACAGTTGTATATG-3 0 . The data were quantified with the 2
ÀDDCt method using simultaneously amplified GAPDH as a reference (primer sequences for GAPDH: sense, 5 0 -CCACCCATGGCAAATTCCATGGCA-3 0 ; antisense, 5 0 -TCTAGACGGCAGGTCAGGTCCACC-3 0 ).
Chromatin immunoprecipitation assays
We used the ChIP-IT chromatin immunoprecipitation kit (Active Motif, Carlsbad, CA, USA) for chromatin immunoprecipitation assays. In brief, cells were fixed with 1% formaldehyde at 37 1C for 5 min, and sonicated to obtain chromatin suspensions. After centrifugation, supernatants were incubated with either antiacetyl histone H3 (Upstate Biotechnology/Millipore, Billerica, MA, USA), anti-Sp1 (Santa Cruz Biotechnology) or rabbit IgG at 4 1C overnight. The mixture was incubated with protein A agarose beads at 4 1C for 1 h, and centrifuged to collect the beads. DNA fragments bound to the beads were purified with vigorous washing, and subjected to PCR using primer pairs spanning À726 to À315 of the CD20 gene.
Mouse lymphoma models
To establish mouse lymphoma models, we inoculated 3 Â 10 6 lymphoma cells intravenously 30 or subcutaneously 19 into 6-to 8-week-old non-obese diabetic/severe combined immunodeficiency mice. Mice were assigned to four treatment groups receiving the vehicle (0.9% NaCl) plus mouse IgG, the vehicle plus rituximab, HDAC inhibitor plus mouse IgG, and HDAC inhibitor plus rituximab after 5 days in case of intravenous injection or when tumors were measurable in case of subcutaneous inoculation. We used either VPA (150 mg/kg twice a day) or romidepsin (0.1 mg/kg once a day) as an HDAC inhibitor. On the basis of previous studies, 30, 31 rituximab was given through the tail vein at 25 mg/kg at 48 h after the administration of HDAC inhibitors. All animal studies were approved by the Animal Ethics Committee of Jichi Medical University, and performed in accordance with the Jichi Medical University Guide for Laboratory Animals, following the Guide for the Care and Use of Laboratory Animals formulated by the National Academy of Sciences.
Results
HDAC inhibitors enhance the expression of CD20 antigen on B-cell lymphoma cells
VPA is a short-chain fatty acid that has been used as an anticonvulsant over 40 years. 32 Recently, VPA was rediscovered as an HDAC inhibitor and has been tested in clinical trials for hematologic malignancies such as myelodysplastic syndrome and acute myeloblastic leukemia. 33, 34 Unfortunately, VPA as a single agent is not so efficacious and so its combination with other drugs is under consideration. Given the ability of HDAC inhibitors to modulate the expression of various cell surface molecules, [21] [22] [23] [24] [25] [26] we reasoned that VPA could enhance the expression of CD20 antigen on B-cell lymphoma cells, which would make VPA and rituximab an effective combination. As anticipated, VPA readily increased CD20 positivity and fluorescence intensity on five Burkitt lymphoma-derived cell lines and a diffuse large B-cell lymphoma cell line B104, in which CD20 expression was relatively low before treatment, but not in another diffuse large B-cell lymphoma cell line TK and a mantle lymphoma cell line HBL-2, which already expressed CD20 very strongly (Table 1 , see Figures 1a and b for representative results) . VPA elicited the effect very rapidly with a significant increase in CD20 being observed after 1-2 days of culture. It is of note that the enhancing effect was evident at 1 mM, a clinically achievable and safe concentration of VPA 35 (Table 2) , whereas apoptosis of target cells was not clear at this concentration (Supplementary Figure S1 and Table S1 ). VPA-induced cell death required 2-5 mM, which apparently exceed the in vivo toxic concentrations, according to cumulative clinical data. 32, 35 This at least partly explains why VPA failed to show considerable effects as a single agent in clinical trials.
We then examined whether another HDAC inhibitor romidepsin (formerly FK228 or depsipeptide) had the same effect. As shown in Table 3 results), romidepsin significantly increased the surface expression of CD20 on Burkitt lymphoma and B104 cells at 5-10 nM, which were far lower than the maximum plasma concentration determined in phase I clinical trials (1.0-1.4 mM). [36] [37] [38] Romidepsin also had remarkable cytotoxic activities at the same concentrations (Supplementary Figure S2 and Table S2 ), consistent with the notion that this drug is one of the most effective HDAC inhibitors against hematological malignancies both in vitro and in vivo. 39, 40 The upregulation of CD20 was not generalized to other B-cell-specific antigens, as the expression levels of CD10, CD21, CD43 and CD44 did not change in response to HDAC inhibitors (data not shown). This negates the possibility that HDAC inhibitors modify the expression of CD20 as a result of differentiation induction in lymphoma cells.
HDAC inhibitors transactivate the CD20 gene through promoter acetylation and Sp1 recruitment
We investigated the molecular mechanisms by which HDAC inhibitors enhanced the surface expression of CD20 antigen on lymphoma cells. First, we performed immunoblotting to examine whether HDAC inhibitors increased the abundance of CD20 protein in three Burkitt lymphoma cell lines and the B104 cell line. As shown in Figure 2a , the amounts of cellular CD20 protein readily increased after 24 h of culture with 1-2 mM VPA in all cell lines examined except for Daudi. In Daudi cells, VPA may facilitate the translocation of CD20 to the cell surface without an increase in protein synthesis as recently reported in certain settings, 41, 42 although the mechanisms underlying this phenomenon are to be clarified. In contrast, HDAC inhibitors did not affect the expression levels of cellular CD20 protein in HBL-2 and TK cells, consistent with the results 23.6 ± 9.8 38.9 ± 13.0 85.6 ± 13.1** 89.7 ± 9.8** Namalwa 16.5 ± 6.3 32.3 ± 13.3* 78.9 ± 14.4** 83.3 ± 15.9** Abbreviation: ND, not done. a The proportion of CD20-positve cells was determined by comparison with the signal intensity of an isotype-matched control. Data are the means ±s.d. of three to five independent experiments. P-values were calculated by one-way analysis of variance with the Bonferroni post hoc test (*Po0.05 and **Po0.01).
of flow cytometry (data not shown). Next, we investigated whether HDAC inhibitors enhanced the expression of CD20 at mRNA levels. Both real-time quantitative reverse transcription PCR (Figure 2b ) and Northern blotting (Supplementary Figure S3) revealed that CD20 mRNA expression was significantly increased by VPA in BJA-B, Namalwa and B104 cells, but not in Daudi cells. These results are fully consistent with the results of immunoblotting, and suggest that VPA activates the transcription of the CD20 gene to increase the abundance of CD20 protein in most cell lines. Romidepsin also increased the expression of CD20 at both protein and mRNA levels in BJA-B, Namalwa and B104 cells (Supplementary Figure S4 and data not shown).
To elucidate the mechanisms of CD20 transactivation by HDAC inhibitors, we carried out chromatin immunoprecipitation assays on CD20 promoter. As illustrated in Figure 2c , the 5 0 -untranslated region of the CD20 gene contains canonical binding sites of Sp1 (À548 to À539; GC-Box), NF-kB (À425 to À417), Oct-1/Oct-2 (À214 to À199), PU.1/IRF4 (À161 to À148) and basic helix-loop-helix proteins (À45 to À40; E-Box) (see Supplementary Figure S5 for nucleotide sequences). Previous investigations have identified Oct-2, PU.1 and an E-Box-binding factor USF1 as positive regulatory elements, which confer lineage-and stage-specific expression of CD20 in B lymphocytes. 43, 44 However, genetic studies using knockout mice indicate that Oct-2 is dispensable for early B-cell development and does not affect the baseline expression of CD20 in immature B lymphocytes. 45 In our pilot experiments, HDAC inhibitors reduced the expressions of PU.1 and USF1 to nearly undetectable levels (data not shown). We therefore focused on the region harboring the binding sites of Sp1 and NF-kB (À726 to À315) in this study. As shown in Figure 2c , VPA enhanced the acetylation of histone H3 in CD20 promoter in BJA-B and Namalwa cells, but not in HBL-2 cells. Promoter acetylation coincided with the enhanced binding of Sp1, which may underlie the transcriptional activation of CD20. This notion is supported by the reduction of Sp1 binding to CD20 promoter in VPA-treated HBL-2 cells, in which CD20 expression was slightly downregulated due to cytotoxic effects of VPA ( Figure 1 and Table 1 ). 
HDAC inhibitors enhance the cytotoxic effect of rituximab in vitro and in vivo
Finally, we examined whether the increased expression of CD20 was linked to the augmentation of the cytotoxic activity of rituximab. To this end, we first carried out in vitro complementdependent cytotoxicity assays and found that HDAC inhibitors significantly enhanced the effect of rituximab at suboptimal concentrations (representative results of VPA-pretreated BJA-B cells are depicted in Figure 3a) . The enhancement was not observed in HBL-2 and TK cells, in which HDAC inhibitors did not further increase CD20 expression (representative results of VPA-pretreated HBL-2 cells are depicted in Figure 3b) . Next, we sought to determine whether this effect could be reproduced in vivo using mouse lymphoma models. First, we established lymphoma models by injecting BJA-B cells into non-obese diabetic/severe combined immunodeficiency mice intravenously. The mice were pretreated with either VPA or vehicle, followed by the administration of either rituximab or control IgG. Injected cells showed the enhancement of CD20 expression ( Figure 4a ) along with histone hyperacetylation (Figure 4b ) in vivo after treatment with HDAC inhibitors. As expected, the increase in CD20 expression led to the enhancement of antilymphoma effects of rituximab; the numbers of CD45-positive cells were significantly lower in the bone marrow of mice pretreated with VPA (Figure 4c ). However, VPA failed to prolong the survival of recipient mice compared with vehicletreated control (data not shown). This might be due to neuronal toxicity of the drug, because VPA-treated mice showed a decrease in food intake and mobility. In addition, intravenously injected BJA-B cells seemed to grow too rapidly to be treated with rituximab alone. We therefore performed the in vivo experiment with the combination of another HDAC inhibitor romidepsin and subcutaneous inoculation of lymphoma cells. As shown in Figure 4d , the size of the subcutaneous tumor constantly increased in vehicle/IgG-treated control mice, and importantly, neither HDAC inhibitor alone nor rituximab alone inhibited tumor growth, consistent with the general consensus that Burkitt lymphoma is untreatable by these drugs as monotherapy. 3, 4, 7 In contrast, tumor growth was significantly retarded when two agents were combined (Figure 4d and Supplementary Figure S6) . These results strongly suggest that HDAC inhibitors can potentiate the effects of rituximab in vivo by enhancing the expression of CD20.
Discussion
It is now widely accepted that rituximab is essential for the treatment of diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma. 3, 4 There are two emerging issues to be resolved for better usage of this drug: weak effects on some tumors [6] [7] [8] and drug resistance. 5, [9] [10] [11] In this study, we clearly demonstrated that HDAC inhibitors, VPA and romidepsin, potentiated the cytotoxic effect of rituximab against Burkitt lymphoma, which has innate resistance to rituximab, 7 by enhancing the expression of surface CD20 antigen both in vitro and in vivo. We also analyzed the mechanisms of CD20 upregulation and found that HDAC inhibitors acetylated core histones of CD20 promoter to enhance the binding of Sp1, leading to transactivation of the CD20 gene in BJA-B and Namalwa cells. These results suggest that the innate resistance of these cells to rituximab is attributable to epigenetic silencing of CD20, which could be overcome by HDAC inhibitors. It is possible that the same mechanism also underlies acquired resistance in lymphomas heavily treated with rituximab. Indeed, Tomita et al. 46 have reported that an HDAC inhibitor, trichostatin A, could restore CD20 expression in a lymphoma cell line established from a patient with follicular lymphoma at the time of CD20-negative transformation after repeated treatment with rituximab. Taken together, HDAC inhibitors are promising agents to overcome both innate and acquired resistance to rituximab in patients with various B-cell malignancies.
HDAC inhibitors appear to upregulate the expression of CD20 specifically, because other B-cell markers such as CD10, CD21, CD43 and CD44 were unaffected. The mechanism underlying this specificity is not fully understood, but previous studies with regard to lineage-restricted expression of these molecules provide a plausible explanation. The expression of CD21 and CD44 was shown to be independent of Sp1, 47, 48 a principal mediator of CD20 transactivation by HDAC inhibitors. Transcription of CD10 and CD43 is governed by Sp1, but is also under the control of DNA methylation in a lineage-specific manner. 49, 50 It is possible that Sp1 is not accessible to methylated CD10 and CD43 promoters of Burkitt lymphoma cells even after the treatment with HDAC inhibitors, although the involvement of other factors cannot be ruled out.
Owing to their unique mechanisms of action, HDAC inhibitors are expected to be effective for tumors resistant to conventional anticancer drugs, and indeed, exerted beneficial effects on peripheral T-cell lymphomas and malignant melanoma in experimental and pilot clinical studies. 16, 40 However, recent clinical trials concluded that HDAC inhibitors had only limited clinical activity when used as monotherapy. 33, 34, [36] [37] [38] Our present study suggests a more effective way of their application; the ability of HDAC inhibitors to modify the expression of surface molecules may provide a new avenue for the clinical application of HDAC inhibitors, for example, as immunopotentiators or chemosensitizers. Hence, the combination with HDAC inhibitors not only enhances anti-lymphoma activity, but also expands the clinical utility of rituximab for other disorders, such as autoimmune diseases.
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